Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Roche Holding AG Basel American Depositary Shares
(OP:
RHHBY
)
39.86
+0.38 (+0.96%)
Streaming Delayed Price
Updated: 1:59 PM EDT, Aug 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
2,671,877
Open
39.74
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
39.48
Today's Range
39.65 - 39.88
52wk Range
29.20 - 41.15
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Merck Stops Lung Cancer Study For Keytruda Combo Due To Ineffective Results, Side Effects
Today 11:51 EDT
Merck discontinues the Phase 3 KeyVibe-008 trial for the fixed-dose combination of vibostolimab and Keytruda in extensive-stage small cell lung cancer due to futility in overall survival and increased...
Via
Benzinga
Here's Why Eli Lilly Stock Dropped 12% Last Month
Today 1:04 EDT
News from a competitor gave investors an unwelcome dose of reality.
Via
The Motley Fool
Performance
YTD
+9.65%
+9.65%
1 Month
+17.61%
+17.61%
3 Month
+31.03%
+31.03%
6 Month
+22.45%
+22.45%
1 Year
+4.97%
+4.97%
More News
Read More
Roche Considers Selling Cancer Data Specialist Flatiron Health Business, Highlights Challenges With Start-Up Acquisitions
August 07, 2024
Via
Benzinga
Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus
August 05, 2024
Via
Benzinga
Are Eli Lilly and Novo Nordisk Too Expensive For You? Here Are 4 Other Potential Weight Loss Stocks You May Want to Consider Right Now.
August 02, 2024
Via
The Motley Fool
Weight Loss Drug Stocks Just Took a Hit. Should You Buy the Stock That Caused It?
July 29, 2024
Via
The Motley Fool
Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On
July 24, 2024
Via
Benzinga
Look Out, Eli Lilly and Novo Nordisk: Could Roche Be the Obesity Drug Stock to Really Watch?
July 23, 2024
Via
The Motley Fool
Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier
July 22, 2024
Via
Benzinga
This Big Pharma Could Become a Leading Weight-Loss Stock. Should You Buy It?
July 22, 2024
Via
The Motley Fool
Better Dark Horse Weight Loss Drug Stock: Pfizer vs. Roche
July 22, 2024
Via
The Motley Fool
Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
July 19, 2024
Via
Investor's Business Daily
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
July 18, 2024
Via
Benzinga
VIX Stages Double-Digit Spike As Risk Off Takes Over; Chipmakers Fail To Rebound, Weight Loss Giants Eli Lilly, Novo Tumble: What's Driving Markets Thursday?
July 18, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
New Data for Genentech’s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions
July 18, 2024
From
Genentech
Via
Business Wire
Why Roche Stock Just Popped, but Eli Lilly and Novo Nordisk Dropped
July 17, 2024
Via
The Motley Fool
Genentech’s Vabysmo Showed Extended Durability, Continued Efficacy and a Consistent Safety Profile in Long-Term Diabetic Macular Edema (DME) Study
July 17, 2024
From
Genentech
Via
Business Wire
Pfizer And Roche Advance On Their Weight Loss Drug Journeys
July 17, 2024
Via
Benzinga
Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?
July 17, 2024
Via
Benzinga
Roche Highlights Encouraging Data From Newly-Acquired Second Weight Loss Drug Candidate In Early-Stage Study
July 17, 2024
Via
Benzinga
Genentech Announces Positive Phase I Results of Its Oral GLP-1 Receptor Agonist CT-996 for the Treatment of People With Obesity
July 17, 2024
From
Genentech
Via
Business Wire
Genentech to Reintroduce Susvimo for People With Wet Age-related Macular Degeneration (AMD)
July 08, 2024
From
Genentech
Via
Business Wire
3 Small-Cap Stocks With Explosive 2X Growth Potential
July 08, 2024
Via
InvestorPlace
Roche's New Immunotherapy Fails To Show Benefit Over Merck's Blockbuster Keytruda In Lung Cancer Patients
July 05, 2024
Via
Benzinga
FDA Approves Genentech’s Vabysmo Prefilled Syringe (PFS) for Three Leading Causes of Vision Loss
July 05, 2024
From
Genentech
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.